Project Grant R01HL167861
Award Date
5/15/25
Completion Date
2/28/30
Dollars Obligated
$688K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Birmingham, AL 35205, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $528,179 to the University of Miami to investigate methods for improving neovascularization in peripheral arterial disease (PAD) and critical limb ischemia (CLI). The key research objectives are to: 1) determine if extracellular vesicles mediate the systemic reprogramming of bone marrow-derived monocytes during ischemia training; 2) examine...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $768,198 to Augusta University Research Institute, Inc. (doing business as Georgia Health Sciences) to conduct research on the function and transcriptional regulation of the gene Leiomodin1 (LMOD1) and its role in coronary artery disease. The research aims to elucidate the in vivo function of LMOD1, a known genetic risk factor for...
This Project Grant award of $2,188,014 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to improve treatment outcomes for peripheral artery disease (PAD). The key objectives are: Develop a novel MRI-histology anatomic scoring system to predict immediate technical failure of percutaneous vascular interventions (PVI) and improve patient selection for PVI procedures. This will involve prospectively imaging PAD...
This federal Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports a 3-year research program focused on elucidating the molecular mechanisms and clinical significance of a specific macrophage population (SPP1+ macrophages) in peripheral arterial disease (PAD). The total award amount is $153,252, with the project period running from September 1, 2024, to August 31, 2027. The key...
This federal Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the connections between cell metabolism, epigenetic regulation, and the transdifferentiation process that allows fibroblasts to transform into endothelial cells. The $1,245,515.38 award, effective from September 1, 2024 to August 31, 2028, will enable the Methodist Hospital Research Institute (HMRI) to...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $761,042 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Pittsburgh to study the mechanisms driving medial arterial calcification (MAC) in peripheral artery disease (PAD). The research aims to define how the DNA damage response suppresses CD73 levels, and how reduced CD73-mediated adenosine production alters arginine methylation to promote osteogenic gene transcription in smooth muscle cells....
This federal Project Grant award, issued by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), provides $660,200 to the University of Louisville to investigate the use of carnosine supplementation as a potential therapeutic intervention for peripheral arterial disease (PAD). The key objectives are to: 1) Evaluate whether carnosine supplementation improves lower extremity function in PAD patients, 2) Conduct mechanistic...
This federal Project Grant award of $686,458, awarded on July 10, 2024 by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports a research project focused on developing a quantitative, predictive model of vascular remodeling in health and disease. The key objective is to acquire quantitative data on the interactions within vascular remodeling regulatory networks and develop a computational model that can accurately...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded a $691,708 project grant (Award ID: R01HL174785) under the Cardiovascular Diseases Research program (CFDA 93.837) to Mayo Clinic to develop a novel contrast-free ultrasound-based quantitative angio flow imaging technique to assess peripheral arterial disease (PAD) of the lower limbs. The key objectives of this 5-year project are to: 1) Determine the efficacy of the new ultrasound-based...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, provides $116,278 to the University of South Florida to investigate the role of the plasminogen activator (PA) pathway in regulating lymphatic valve defects associated with lymphatic malformations. The researchers will assess the expression of key PA enzymes and utilize in vitro zymography to evaluate matrix metalloproteinase (MMP) activation,...